SPRY
ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M
ARS Pharmaceuticals reports Q4 loss of $0.42/share as revenue surges 332% YoY to $28.1M despite sequential decline from Q3 peak.
ARS Pharmaceuticals reports Q4 loss of $0.42/share as revenue surges 332% YoY to $28.1M despite sequential decline from Q3 peak.